• 폴리머
• /
• 제37권6호
• /
• pp.702-710
• /
• 2013

서방성방출을 위해 잘토프로펜을 함유한 미립구를 oil-in-water(O/W) 에멀젼용매 증발법을 이용하여 제조하였다. 제조온도, 교반속도, 초음파분쇄기의 강도, 약물농도, POX의 분자량과 농도, 유화제 농도 등의 제조조건에 따른 잘토프로펜의 방출거동을 평가하였다. 잘토프로펜을 함유한 POX 미립구의 물리화학적 성질 및 형태를 X선 회절분석법(XRD)과 시차주사열량계(DSC), 적외선 분광분석기(FTIR), 주사현미경(SEM)을 통해 연구하였다. 이러한 연구 결과로부터 제조조건들에 따른 미립구의 특성을 확인할 수 있었다. 또한 POX 미립구의 분해성을 10일 동안 in vitro 실험을 통해 조사하였다. 본 연구를 통해 잘토프로펜을 함유한 POX 미립구를 최적화된 용매증발방법으로 제조하였고, 이 미립구로부터 약물의 방출제어를 확인할 수 있었다.

• Archives of Pharmacal Research
• /
• 제26권1호
• /
• pp.76-82
• /
• 2003

Drug releasing porous poly($\varepsilon$-caprolactone) (PCL)-chitosan matrices were fabricated for bone regenerative therapy. Porous matrices made of biodegradable polymers have been playing a crucial role as bone substitutes and as tissue-engineered scaffolds in bone regenerative therapy. The matrices provided mechanical support for the developing tissue and enhanced tissue formation by releasing active agent in controlled manner. Chitosan was employed to enhance hydrophilicity and biocompatibility of the PCL matrices. PDGF-BB was incorporated into PCL-chitosan matrices to induce enhanced bone regeneration efficacy. PCL-chitosan matrices retained a porous structure with a 100-200 $\mu$m pore diameter that was suitable for cellular migration and osteoid ingrowth. $NaHCO_3$ as a porogen was incorporated 5% ratio to polymer weight to form highly porous scaffolds. PDGF-BB was released from PCL-chitosan matrices maintaining therapeutic concentration for 4 week. High osteoblasts attachment level and proliferation was observed from PCL-chitosan matrices. Scanning electron microscopic examination indicated that cultured osteoblasts showed round form and spread pseudopods after 1 day and showed broad cytoplasmic extension after 14 days. PCL-chitosan matrices promoted bone regeneration and PDGF-BB loaded matrices obtained enhanced bone formation in rat calvarial defect. These results suggested that the PDGF-BB releasing PCL-chitosan porous matrices may be potentially used as tissue engineering scaffolds or bone substitutes with high bone regenerative efficacy.

• 폴리머
• /
• 제37권3호
• /
• pp.347-355
• /
• 2013

본 연구에서는 항산화제인 quercetin과 그 배당체인 rutin의 피부 흡수를 증진시키기 위한 전달체로 다공성 셀룰로오스 하이드로젤을 제조하였고 그 특성을 연구하였다. Quercetin과 rutin을 위한 최적의 하이드로젤을 가교제인 12% epichlorohydrin(ECH)과 2% 셀룰로오스를 반응용액으로 하여 만들었다. 플라보노이드 함유 하이드로젤의 방출 실험에서, quercetin의 방출은 $10{\sim}500{\mu}M$ 농도에서 확산 속도에 영향을 받았으나, rutin의 경우는 비교적 낮은 농도($10{\sim}50{\mu}M$)에서 하이드로젤의 침식에 의한 방출이 지배적이었다. 플라보노이드에 대한 하이드로젤의 포집효율과 방출량은 quercetin보다도 rutin에서 모두 크게 나타났다. 하지만, Franz diffusion cell을 이용한 피부 투과 실험에서 quercetin이 rutin보다 1.2배나 더 큰 피부 투과능을 나타냈다. 플라보노이드 함유 하이드로젤은 대조군인 20% 1,3-butylene glycol phosphate buffer에서보다도 더 큰 경피 투과능을 나타내었다. 이 결과들은 난용성 항산화제인 플라보노이드의 피부 흡수 증진 전달체로서 셀룰로오스 다공성 하이드로젤이 이용 가능성이 있음을 시사한다.

• Journal of Ginseng Research
• /
• 제39권1호
• /
• pp.22-28
• /
• 2015

Background: Sun ginseng (SG), a specific formulation of quality-controlled red ginseng, contains approximately equal amounts of three major ginsenosides (RK1, Rg3, and Rg5), which reportedly has antitumor-promoting activities in animal models. Methods: MTT assay was used to assess whether SG can potentiate the anticancer activity of epirubicin or paclitaxel in human cervical adenocarcinoma HeLa cells, human colon cancer SW111C cells, and SW480 cells; apoptosis status was analyzed by annexin V-FITC and PI and analyzed by flow cytometry; and apoptosis pathway was studied by analysis of caspase-3, -8, and -9 activation, mitochondrial accumulation of Bax and Bak, and cytochrome c release. Results: SG remarkably enhances cancer cell death induced by epirubicin or paclitaxel in human cervical adenocarcinoma HeLa cells, human colon cancer SW111C cells, and SW480 cells. Results of the mechanism study highlighted the cooperation between SG and epirubicin or paclitaxel in activating caspase-3 and -9 but not caspase-8. Moreover, SG significantly increased the mitochondrial accumulation of both Bax and Bak triggered by epirubicin or paclitaxel as well as the subsequent release of cytochrome c in the targeted cells. Conclusion: SG significantly potentiated the anticancer activities of epirubicin and paclitaxel in a synergistic manner. These effects were associated with the increased mitochondrial accumulation of both Bax and Bak that led to an enhanced cytochrome c release, caspase-9/-3 activation, and apoptosis. Treating cancer cells by combining epirubicin and paclitaxel with SG may prove to be a novel strategy for enhancing the efficacy of the two drug types.

• 대한화장품학회지
• /
• 제30권3호
• /
• pp.295-305
• /
• 2004

콜로이드와 계면화학은 표면적과 표면에너지의 학문이다. 계면상의 위치에 따라서 분자밀도, 분자간의 상호작용력, 분자 배향성 그리고 반응성이 달라진다는 것은 흥미있는 주제가 되고 있다. 이러한 계면에너지가 중요하게 작용하는 시스템으로서 회합체, 에멀젼, 입자분산, 거품, 2차원적 표면이나 필름을 들 수 있다. 특히 나노 입자에 관련된 생체 적합성 재료를 사용하여 약물 전달체와 화장품 나노 소재로 이용하는데 관심이 고조되고 있다. 나노 입자는 수 nm에서 수백 nm 크기를 갖는, 넓은 표면적을 가진 콜로이드 상의 불균일 분산 입자의 일종이다. 지금까지 나노 입자의 제조, 특성 규명, 나노입자를 이용한 약물 봉입에 관한 연구가 활발히 이루어져 약물 전달체로서의 가능성이 충분히 입증되었다. 또한 난용성분 가용화 나노소재, 피부 흡수 증진용 나노소재, 자외선 차단용 나노소재, 안정화용 나노소재, 서방형 나노소재 등의 화장품 연구에 생체적합 나노전달체를 이용한 예가 보고되었다. 나노/마이크로 입자 시스템은 제조방법과 형태에 따라 나노/마이크로 스피어, 나노/마이크로 캡슐, 나노/마이크로 에멀젼, 폴리머 마이셀, 리포좀 등으로 구분된다. 수용액상에서 자기 회합체를 구성하는 나노수준의 폴리머 마이셀입자, 고농도, 고활성 물질에 대하여 농도 및 활성을 일정하게 제어할 수 있는 나노/마이크로 캡슐, 단일 이중층 또는 다층(100~800 nm)을 형성하여 여러 생리 환성 물질의 전달체로 이용되는 리포솜(liposome)에 대하여 제조방법과 산업의 응용에 대해 소개하였다.

• 폴리머
• /
• 제29권6호
• /
• pp.599-604
• /
• 2005

생체적합성이 우수한 히아루론산과 생분해성이 우수한 폴리락타이드의 이량체인 락타이드를 결합하여 인체내에서 분해속도를 조절할 수 있는 생체적합성이 우수한 생체재료를 제조하였다. 냉동 건조법을 이용하여 히아루론산과 락타이드를 가교제 1-ethyl-3-(3-dimethyl aminopnpyl) carbodiimide(EDC)로 가교시켰다. 생성된 막을 핵자기 공명분광법으로 분석하여 젖산기 반응도와 EDC 반응도를 결정하였다. 히아루론산에 대한 락타이드의 몰비가 5부터 13까지 증가함에 따라 젖산기 반응도와 EDC 반응도는 증가하였다. 몰비가 커서 젖산기가 많이 첨가되면 팽윤도는 감소하고 취성이 강해졌다. 또 가교제 농도를 증가시키거나 가교 온도를 감소시키면 젖산기가 더욱 첨가되어 팽윤도는 감소하고 탄성률은 증가하였다. 서로 다른 가교도를 가진 막에 대해 약물 방출 실험을 한 결과 막의 가교도가 증가함에 따라 약물의 투과도는 감소하였다. 몰비가 커 젖산기가 많이 첨가된 고분자일수록 늦게 분해되었다. 몰비, 온도, 가교제 농도 등의 운전 변수를 조절하여 막의 기계적 물성과 분해 속도가 적절히 조절될 수 있었다.

• 한국수정란이식학회지
• /
• 제26권1호
• /
• pp.1-7
• /
• 2011

The purpose of this study was to determine the relationship between conception rate and other parameters (body condition score; BCS, progesterone concentrations and follicle size) before estrus induction with CIDR(intravaginal progesterone-releasing controlled internal drug release). The conception rate in cows with < 2.75, 2.75 to 3.25, and 3.25 <, BCS regardless of AI (artificial insemination) time was 46.6%, 63.3%, and 46.6% at CIDR insertion, respectively. The conception rate regardless of BCS was 54.9% in cows inseminated based on detected estrus, and 48.7% in cows inseminated at 72 to 80 hours (timed artificial insemination, TAI) after removal of CIDR. The conception rate regardless of AI time was 40.0% in cows with low progesterone concentrations (less than 1.0 ng/ml), and 56.6% in cows with high progesterone concentrations (more than 1.0 ng/ml) at CIDR injection. The conception rate regardless of progesterone concentrations was 53.8% in cows inseminated based on detected estrus, and 38.0% in cows of TAI after removal of CIDR. The conception rate regardless of AI time was 43.3% in cows with small follicle (less than 5 mm), 53.3% in cows between 5 mm to 10 mm of follicle, and 63.3% in cows with large folliclc (more than 10 mm) at CIDR injection, respectively. The conception rate regardless of follicle size was 58.4% in cows inseminated based on detected estrus, and 45.9% in cows of TAI after removal of CIDR. These results indicated that if the cows with BCS 2.75 to 3.25, active corpus luteum, and/or large dominant follicle (more than 10 mm) are used for estrus induction, the conception rate will be greater.

• 한국수정란이식학회지
• /
• 제26권2호
• /
• pp.91-96
• /
• 2011

The purpose of this study was to evaluate the effects of days open on subsequent reproductive performance following to estrus synchronization in the 114 lactating dairy cows. The animals were divided into two groups according to the time of estrus synchronization; viz, ${\leq}$ 85 days, and > 85 days postpartum, respectively. The estrus synchronization protocol consisted of insertion of a controlled internal drug release (CIDR) device containing 1.9 g progesterone with an injection of 250 ${\mu}g$ gonadorelin (Day 0), an injection of $PGF_2{\alpha}$ and removal of the device on Day 7, an injection of 250 ${\mu}g$ GnRH on Day 9, and TAI 17 h later. Pregnancy diagnosis was determined at 30 to 60 days after TAI using both ultrasonography and rectal palpation. The body condition score (BCS) gradually increased over the postpartum period. In estrus synchronized cows until 85 days, conception rate on first service, number of service per conception, interval from estrus synchronization to conception, and interval from calving to conception were not significantly different among two farms (P>0.05). In estrus synchronized cows after 85 days postpartum, conception rate on first service, number of service per conception and interval from calving to conception were significantly different ($P{\leq}0.05$) between herds A and B (26.8 vs 50.0%; $2.1{\pm}1.35$ vs $1.37{\pm}0.54$ times, $237.3{\pm}97.8$ vs $164.7{\pm}69.3$ days, respectively). In estrus synchronized cows after 85 days postpartum interval from estrus synchronization to conception was greater (P<0.01) in herd B than in herd A ($63.6{\pm}57.4$ vs $26.1{\pm}24.9$). These results indicate that the time of estrus synchronization for maximized the reproductive performance is before 85 days postpartum and feeding and management is important factor for high reproductive performance.

• Asian-Australasian Journal of Animal Sciences
• /
• 제27권9호
• /
• pp.1270-1275
• /
• 2014

An experiment was conducted to evaluate the efficacy of porcine follicle stimulating hormone (pFSH) dosage based on body weight (BW) on ovarian responses of crossbred does. Thirty donor does were divided into 3 groups getting pFSH dosages of 3, 5, and 8 mg pFSH per kg BW, respectively, and were named as pFSH-3, pFSH-5 and pFSH-8, respectively. Estrus was synchronized by inserting a controlled internal drug release (CIDR) device and a single injection of prostaglandin $F2{\alpha}$ ($PGF2{\alpha}$). The pFSH treatments were administered twice a day through 6 decreasing dosages (25, 25, 15, 15, 10, and 10% of total pFSH amount; decreasing daily). Ovarian responses were evaluated on Day 7 after CIDR removal. After CIDR removal, estrus was observed 3 times in a day and pFSH treatments were initiated at 2 days before the CIDR removal. All does in pFSH-5 and pFSH-8 showed estrus signs while half of the does in pFSH-3 showed estrus signs. No differences (p>0.05) were observed on the corpus luteum and total ovarian stimulation among the treatment groups, while total and transferable embryos were higher (p<0.05) in pFSH-5 (7.00 and 6.71) than pFSH-3 (3.00 and 2.80) and pFSH-8 (2.00 and 1.50), respectively. In conclusion, 5 mg pFSH per kg BW dosage gave a higher number of embryos than 3 and 8 mg pFSH per kg BW dosages. The results indicated that the dosage of pFSH based on BW is an important consideration for superovulation in goats.

• Reproductive and Developmental Biology
• /
• 제37권1호
• /
• pp.29-33
• /
• 2013

The objective of this work was to analyze the concentrations of progesterone (P4) and estrogen (E2) hormones changed during estrus synchronization in dairy heifers. Estrus synchronization was carried out with CIDR$^{(R)}$ (Controlled Intravaginal Drug Release) devices. Corpus luteum (CL) was classified into three grades based on its size and palpable characteristics. The concentrations of P4 and E2 were measured by enzyme-amplified chemiluminescence. Serum P4 concentration was markedly low at the estrus stage (36 hrs after removal of CIDR) compared to other stages, while E2 concentration was kept high during estrus stage. The serum P4 concentration was highest in the CL classified into grade I. These results indicate that P4 concentration could be used as a criteria for determining recipients for artificial insemination or embryo transfer in dairy cattle.